<p>随着我们进入 2026 年 1 月，亚洲市场正在应对一个充满对人工智能的乐观情绪和对经济增长预测谨慎的环境，尤其是在中国和日本。在这样的环境中，识别被低估的股票可以为寻求利用市场低效的投资者提供潜在机会。</p>
<h3>基于现金流的亚洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>Visional (TSE:4194)</td>
<td>¥10010.00</td>
<td>¥19887.98</td>
<td>49.7%</td>
</tr>
<tr>
<td>Takara Bio (TSE:4974)</td>
<td>¥795.00</td>
<td>¥1580.06</td>
<td>49.7%</td>
</tr>
<tr>
<td>Nan Juen International (TPEX:6584)</td>
<td>NT$347.00</td>
<td>NT$687.14</td>
<td>49.5%</td>
</tr>
<tr>
<td>Kuraray (TSE:3405)</td>
<td>¥1587.00</td>
<td>¥3163.27</td>
<td>49.8%</td>
</tr>
<tr>
<td>JINS HOLDINGS (TSE:3046)</td>
<td>¥5530.00</td>
<td>¥11032.70</td>
<td>49.9%</td>
</tr>
<tr>
<td>Innovent Biologics (SEHK:1801)</td>
<td>HK$76.25</td>
<td>HK$151.11</td>
<td>49.5%</td>
</tr>
<tr>
<td>Forth Corporation (SET:FORTH)</td>
<td>THB5.75</td>
<td>THB11.21</td>
<td>48.7%</td>
</tr>
<tr>
<td>Daiichi Sankyo Company (TSE:4568)</td>
<td>¥3348.00</td>
<td>¥6544.37</td>
<td>48.8%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥801.00</td>
<td>¥1581.79</td>
<td>49.4%</td>
</tr>
<tr>
<td>Aidma Holdings (TSE:7373)</td>
<td>¥3160.00</td>
<td>¥6305.80</td>
<td>49.9%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们基于现金流的 260 只被低估的亚洲股票的完整列表。</p>
<p>让我们深入探讨一些筛选出的优质选择。</p>
<h2>CLASSYS (KOSDAQ:A214150)</h2>
<p><strong>概述：</strong> CLASSYS Inc. 是一家全球医疗美容设备提供商，市值为 3.56 万亿韩元。</p>
<p><strong>运营：</strong> 该公司主要通过其外科和医疗设备部门产生收入，金额为 3178 亿韩元。</p>
<p><strong>公允价值折扣估算：</strong> 42%</p>
<p>CLASSYS 的交易价格显著低于其估算的公允价值 94,028.53 韩元，折扣达到 42%。尽管 2025 年第三季度销售略有下降，但净收入与去年相比增长了两倍多。过去一年，收益增长了 39.1%，预计将以 30.9% 的年率继续显著增长。分析师一致认为，价格有潜在上涨约 33.8%。</p>
<ul>
<li>根据我们的收益增长报告，CLASSYS 可能准备扩展。</li>
<li>通过我们的全面财务健康报告深入了解 CLASSYS 的具体情况。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b611d0d-1cc3-4214-96d4-f413526dfa5f/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b611d0d-1cc3-4214-96d4-f413526dfa5f/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>KOSDAQ:A214150 截至 2026 年 1 月的折现现金流</p>
<h2>北汽福田汽车有限公司 (SHSE:600166)</h2>
<p><strong>概述：</strong> 北汽福田汽车有限公司从事全球商用车的制造和销售，市值为 231.2 亿人民币。</p>
<p><strong>运营：</strong> 北汽福田汽车有限公司通过其全球商用车制造和销售业务产生收入。</p>
<p><strong>公允价值折扣估算：</strong> 34%</p>
<p>北汽福田汽车有限公司的交易价格为 2.92 元人民币，显著低于其估算的公允价值 4.43 元人民币，表明基于现金流的潜在低估。该公司过去一年收益增长了 37.6%，预计将以 39.14% 的年率增长，超过中国市场 27.5% 的平均增长率。最近在新能源车平台上的创新突显了福田在可持续物流解决方案上的战略重点，可能增强未来的现金流和盈利能力。</p>
<ul>
<li>我们的北汽福田汽车有限公司增长报告中的分析暗示未来财务表现强劲。</li>
<li>通过阅读我们的健康报告，深入了解北汽福田汽车有限公司的资产负债表。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39388ef9-2d0b-4a73-8167-7e0f574839c7/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39388ef9-2d0b-4a73-8167-7e0f574839c7/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:600166 截至 2026 年 1 月的折现现金流</p>
<h2>厦门特宝生物科技有限公司 (SHSE:688278)</h2>
<p><strong>概述：</strong> 厦门特宝生物科技有限公司专注于重组蛋白药物的研究、开发、生产和销售，市值为 341.6 亿人民币。</p>
<p><strong>运营：</strong> 该公司的收入主要来自其生物制药部门，产生了 33.4 亿人民币。</p>
<p><strong>公允价值折扣估算：</strong> 48.5%</p>
<p>厦门特宝生物科技的交易价格为 83.68 元人民币，远低于其估算的公允价值 162.36 元人民币，表明其基于现金流的低估。该公司过去一年收益增长了 26.9%，预计将以 34.1% 的年率显著增长，超过中国市场 27.5% 的平均增长率。尽管非现金收益较高，但强劲的收入增长预测和高股本回报率的预期支持其改善财务表现的潜力。</p>
<ul>
<li>我们编制的增长报告表明，厦门特宝生物科技的未来前景可能向好。</li>
<li>在这份财务健康报告中解锁我们对厦门特宝生物科技股票分析的全面见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/21048bb0-3258-4ed1-9566-6eac36ea690b/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/21048bb0-3258-4ed1-9566-6eac36ea690b/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:688278 截至 2026 年 1 月的折现现金流</p>
<h2>抓住机会</h2>
<ul>
<li>通过使用我们的筛选器，深入了解所有 260 只基于现金流的被低估的亚洲股票。</li>
<li>是这些公司的股东之一吗？确保您不会错过任何重要的股票动态，通过在 Simply Wall St 中添加您的投资组合来获得及时提醒。</li>
<li>Simply Wall St 是一款为长期股票投资者设计的革命性应用，免费且覆盖全球所有市场。</li>
</ul>
<h2>准备好不同的投资方式吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠的收入来源来分散您的投资组合，以应对潜在的市场动荡。</li>
<li>通过分析师和管理层的乐观展望，推动您的投资组合中显示强劲增长潜力的公司。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您带来以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
<p>国防与灾难的移动基础设施</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

特宝生物

福田汽车

<p>截至 2026 年 1 月，亚洲市场对人工智能持乐观态度，但对经济增长保持谨慎，尤其是在中国和日本。投资者被鼓励探索被低估的股票，其中值得关注的包括 CLASSYS、北汽福田汽车和厦门特宝生物，这些股票的交易价格均显著低于其估计的公允价值。CLASSYS 的折扣为 42%，北汽福田为 34%，厦门特宝生物为 48.5%。这些公司展现出强劲的盈利增长潜力，使其成为寻求当前市场机会的投资者的吸引选项</p>

<p>As we enter January 2026, Asian markets are navigating a landscape marked by optimism around artificial intelligence and cautious economic growth forecasts, particularly in China and Japan. In such an environment, identifying undervalued stocks can offer potential opportunities for investors seeking to capitalize on market inefficiencies.</p>
<div class="lb-trans"><p>随着我们进入 2026 年 1 月，亚洲市场正在应对一个充满对人工智能的乐观情绪和对经济增长预测谨慎的环境，尤其是在中国和日本。在这样的环境中，识别被低估的股票可以为寻求利用市场低效的投资者提供潜在机会。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基于现金流的亚洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Visional (TSE:4194)</td>
<td>¥10010.00</td>
<td>¥19887.98</td>
<td>49.7%</td>
</tr>
<tr>
<td>Takara Bio (TSE:4974)</td>
<td>¥795.00</td>
<td>¥1580.06</td>
<td>49.7%</td>
</tr>
<tr>
<td>Nan Juen International (TPEX:6584)</td>
<td>NT$347.00</td>
<td>NT$687.14</td>
<td>49.5%</td>
</tr>
<tr>
<td>Kuraray (TSE:3405)</td>
<td>¥1587.00</td>
<td>¥3163.27</td>
<td>49.8%</td>
</tr>
<tr>
<td>JINS HOLDINGS (TSE:3046)</td>
<td>¥5530.00</td>
<td>¥11032.70</td>
<td>49.9%</td>
</tr>
<tr>
<td>Innovent Biologics (SEHK:1801)</td>
<td>HK$76.25</td>
<td>HK$151.11</td>
<td>49.5%</td>
</tr>
<tr>
<td>Forth Corporation (SET:FORTH)</td>
<td>THB5.75</td>
<td>THB11.21</td>
<td>48.7%</td>
</tr>
<tr>
<td>Daiichi Sankyo Company (TSE:4568)</td>
<td>¥3348.00</td>
<td>¥6544.37</td>
<td>48.8%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥801.00</td>
<td>¥1581.79</td>
<td>49.4%</td>
</tr>
<tr>
<td>Aidma Holdings (TSE:7373)</td>
<td>¥3160.00</td>
<td>¥6305.80</td>
<td>49.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>Visional (TSE:4194)</td>
<td>¥10010.00</td>
<td>¥19887.98</td>
<td>49.7%</td>
</tr>
<tr>
<td>Takara Bio (TSE:4974)</td>
<td>¥795.00</td>
<td>¥1580.06</td>
<td>49.7%</td>
</tr>
<tr>
<td>Nan Juen International (TPEX:6584)</td>
<td>NT$347.00</td>
<td>NT$687.14</td>
<td>49.5%</td>
</tr>
<tr>
<td>Kuraray (TSE:3405)</td>
<td>¥1587.00</td>
<td>¥3163.27</td>
<td>49.8%</td>
</tr>
<tr>
<td>JINS HOLDINGS (TSE:3046)</td>
<td>¥5530.00</td>
<td>¥11032.70</td>
<td>49.9%</td>
</tr>
<tr>
<td>Innovent Biologics (SEHK:1801)</td>
<td>HK$76.25</td>
<td>HK$151.11</td>
<td>49.5%</td>
</tr>
<tr>
<td>Forth Corporation (SET:FORTH)</td>
<td>THB5.75</td>
<td>THB11.21</td>
<td>48.7%</td>
</tr>
<tr>
<td>Daiichi Sankyo Company (TSE:4568)</td>
<td>¥3348.00</td>
<td>¥6544.37</td>
<td>48.8%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥801.00</td>
<td>¥1581.79</td>
<td>49.4%</td>
</tr>
<tr>
<td>Aidma Holdings (TSE:7373)</td>
<td>¥3160.00</td>
<td>¥6305.80</td>
<td>49.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 260 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>点击这里查看我们基于现金流的 260 只被低估的亚洲股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of the screener.</p>
<div class="lb-trans"><p>让我们深入探讨一些筛选出的优质选择。</p>
</div><h2>CLASSYS (KOSDAQ:A214150)</h2>
<div class="lb-trans"><h2>CLASSYS (KOSDAQ:A214150)</h2>
</div><p><strong>Overview:</strong> CLASSYS Inc. is a global provider of medical aesthetics devices with a market capitalization of ₩3.56 trillion.</p>
<div class="lb-trans"><p><strong>概述：</strong> CLASSYS Inc. 是一家全球医疗美容设备提供商，市值为 3.56 万亿韩元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its Surgical &amp; Medical Equipment segment, amounting to ₩317.80 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其外科和医疗设备部门产生收入，金额为 3178 亿韩元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 42%</p>
<div class="lb-trans"><p><strong>公允价值折扣估算：</strong> 42%</p>
</div><p>CLASSYS is trading at a significant discount, 42% below its estimated fair value of ₩94,028.53. Despite a slight decline in sales for the third quarter of 2025, net income more than doubled compared to the previous year. Earnings have grown by 39.1% over the past year and are expected to continue growing significantly at an annual rate of 30.9%. Analysts agree on a potential price increase of about 33.8%.</p>
<div class="lb-trans"><p>CLASSYS 的交易价格显著低于其估算的公允价值 94,028.53 韩元，折扣达到 42%。尽管 2025 年第三季度销售略有下降，但净收入与去年相比增长了两倍多。过去一年，收益增长了 39.1%，预计将以 30.9% 的年率继续显著增长。分析师一致认为，价格有潜在上涨约 33.8%。</p>
</div><ul>
<li>According our earnings growth report, there's an indication that CLASSYS might be ready to expand.</li>
<li>Dive into the specifics of CLASSYS here with our thorough financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>根据我们的收益增长报告，CLASSYS 可能准备扩展。</li>
<li>通过我们的全面财务健康报告深入了解 CLASSYS 的具体情况。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b611d0d-1cc3-4214-96d4-f413526dfa5f/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/0b611d0d-1cc3-4214-96d4-f413526dfa5f/chart/dcf?theme=light"/></p>
<p>KOSDAQ:A214150 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>KOSDAQ:A214150 截至 2026 年 1 月的折现现金流</p>
</div><h2>Beiqi Foton MotorLtd (SHSE:600166)</h2>
<div class="lb-trans"><h2>北汽福田汽车有限公司 (SHSE:600166)</h2>
</div><p><strong>Overview:</strong> Beiqi Foton Motor Co., Ltd. is involved in the manufacture and sale of commercial vehicles globally, with a market cap of CN¥23.12 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 北汽福田汽车有限公司从事全球商用车的制造和销售，市值为 231.2 亿人民币。</p>
</div><p><strong>Operations:</strong> Beiqi Foton Motor Co., Ltd. generates revenue through its global operations in the commercial vehicle manufacturing and sales sector.</p>
<div class="lb-trans"><p><strong>运营：</strong> 北汽福田汽车有限公司通过其全球商用车制造和销售业务产生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 34%</p>
<div class="lb-trans"><p><strong>公允价值折扣估算：</strong> 34%</p>
</div><p>Beiqi Foton Motor Ltd. is trading at CN¥2.92, significantly below its estimated fair value of CN¥4.43, indicating a potential undervaluation based on cash flows. The company's earnings have grown by 37.6% over the past year and are forecast to grow at 39.14% annually, outpacing the Chinese market's average growth rate of 27.5%. Recent innovations in new energy vehicle platforms highlight Foton's strategic focus on sustainable logistics solutions, potentially enhancing future cash flows and profitability.</p>
<div class="lb-trans"><p>北汽福田汽车有限公司的交易价格为 2.92 元人民币，显著低于其估算的公允价值 4.43 元人民币，表明基于现金流的潜在低估。该公司过去一年收益增长了 37.6%，预计将以 39.14% 的年率增长，超过中国市场 27.5% 的平均增长率。最近在新能源车平台上的创新突显了福田在可持续物流解决方案上的战略重点，可能增强未来的现金流和盈利能力。</p>
</div><ul>
<li>The analysis detailed in our Beiqi Foton MotorLtd growth report hints at robust future financial performance.</li>
<li>Get an in-depth perspective on Beiqi Foton MotorLtd's balance sheet by reading our health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们的北汽福田汽车有限公司增长报告中的分析暗示未来财务表现强劲。</li>
<li>通过阅读我们的健康报告，深入了解北汽福田汽车有限公司的资产负债表。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39388ef9-2d0b-4a73-8167-7e0f574839c7/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/39388ef9-2d0b-4a73-8167-7e0f574839c7/chart/dcf?theme=light"/></p>
<p>SHSE:600166 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:600166 截至 2026 年 1 月的折现现金流</p>
</div><h2>Xiamen Amoytop Biotech (SHSE:688278)</h2>
<div class="lb-trans"><h2>厦门特宝生物科技有限公司 (SHSE:688278)</h2>
</div><p><strong>Overview:</strong> Xiamen Amoytop Biotech Co., Ltd. focuses on the research, development, production, and sale of recombinant protein drugs both in China and internationally, with a market cap of CN¥34.16 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 厦门特宝生物科技有限公司专注于重组蛋白药物的研究、开发、生产和销售，市值为 341.6 亿人民币。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its biologics segment, which generated CN¥3.34 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的收入主要来自其生物制药部门，产生了 33.4 亿人民币。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 48.5%</p>
<div class="lb-trans"><p><strong>公允价值折扣估算：</strong> 48.5%</p>
</div><p>Xiamen Amoytop Biotech is trading at CN¥83.68, well below its estimated fair value of CN¥162.36, suggesting it is undervalued based on cash flows. The company's earnings have grown by 26.9% over the past year and are forecast to grow significantly at 34.1% annually, surpassing the Chinese market's average growth rate of 27.5%. Despite high non-cash earnings, strong revenue growth projections and a high return on equity forecast support its potential for improved financial performance.</p>
<div class="lb-trans"><p>厦门特宝生物科技的交易价格为 83.68 元人民币，远低于其估算的公允价值 162.36 元人民币，表明其基于现金流的低估。该公司过去一年收益增长了 26.9%，预计将以 34.1% 的年率显著增长，超过中国市场 27.5% 的平均增长率。尽管非现金收益较高，但强劲的收入增长预测和高股本回报率的预期支持其改善财务表现的潜力。</p>
</div><ul>
<li>The growth report we've compiled suggests that Xiamen Amoytop Biotech's future prospects could be on the up.</li>
<li>Unlock comprehensive insights into our analysis of Xiamen Amoytop Biotech stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们编制的增长报告表明，厦门特宝生物科技的未来前景可能向好。</li>
<li>在这份财务健康报告中解锁我们对厦门特宝生物科技股票分析的全面见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/21048bb0-3258-4ed1-9566-6eac36ea690b/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/21048bb0-3258-4ed1-9566-6eac36ea690b/chart/dcf?theme=light"/></p>
<p>SHSE:688278 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:688278 截至 2026 年 1 月的折现现金流</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住机会</h2>
</div><ul>
<li>Get an in-depth perspective on all 260 Undervalued Asian Stocks Based On Cash Flows by using our screener here.</li>
<li>Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.</li>
<li>Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过使用我们的筛选器，深入了解所有 260 只基于现金流的被低估的亚洲股票。</li>
<li>是这些公司的股东之一吗？确保您不会错过任何重要的股票动态，通过在 Simply Wall St 中添加您的投资组合来获得及时提醒。</li>
<li>Simply Wall St 是一款为长期股票投资者设计的革命性应用，免费且覆盖全球所有市场。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>准备好不同的投资方式吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠的收入来源来分散您的投资组合，以应对潜在的市场动荡。</li>
<li>通过分析师和管理层的乐观展望，推动您的投资组合中显示强劲增长潜力的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您带来以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>国防与灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

2026 年 1 月预计被低估的 3 只亚洲股票